Tenofovir + Levonorgestrel IVR
Polyurethane, dual-reservoir ring designed for 3 months of continuous use, or with up to 3 days intermittent removal. The first-in-women Phase I trial (CONRAD-128) completed in 2016 and successfully met all performance benchmarks. An expanded Phase I study (CONRAD-138) was completed in 2019. A first-in-kind study to evaluate MPT IVRs in Africa, the CDC Kisumu Combined Ring Study (CONRAD B17-144) was also completed in late 2019.
Development Stage:
Clinical – Phase 2 Trial (C2)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Topical - Intravaginal Ring (IVR)
Mechanism of Action:
nucleoside analogue reverse transcriptase inhibitor (NRTI), progestin
Developer:
- CONRAD
Funding:
Funding Mechanism:
None
Past Funding:
Center for Disease Control and Prevention (CDC)
U.S. Agency for International Development (USAID)
Active Ingredient(s):
- Levonorgestrel
- Tenofovir (TFV)
Product Indication(s):
- HIV
- HSV-2
- Pregnancy